Iwona Buczyńska

Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection

Robert Flisiak, Dorota Zarębska‐Michaluk, Jerzy Jaroszewicz et al. · Polskie Archiwum Medycyny Wewnętrznej · 2020 · 24 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Liver Injury in Patients with COVID-19 without Underlying Liver Disease

Monika Pazgan−Simon, Syłwia Serafińska, Michał Kukla et al. · Journal of Clinical Medicine · 2022 · 24 citations · Full text

Medicine, Infectious Diseases, Pathology +16

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

Jerzy Jaroszewicz, Małgorzata Pawłowska, Krzysztof Simon et al. · Expert Review of Anti-infective Therapy · 2020 · 19 citations · Full text

Medicine, Infectious Diseases, Hepatology +13

Real‐world effectiveness and safety of direct‐acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study

Aleksandra Berkan‐Kawińska, Anna Piekarska, Ewa Janczewska et al. · Liver International · 2021 · 18 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study

Anna Piekarska, Elżbieta Jabłonowska, Aleksander Garlicki et al. · AIDS Care · 2019 · 15 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +12